Home › Research › Treatments
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial
Sato Y, Honda Y, Umeno K, Hayashida N, Iwamoto J, Takeda T, Matsumoto H.. The Kurume medical journal, 2011-01-01
This paper has been retracted. The record we hold marks it as a retracted publication. Check the original source below for the retraction notice before relying on anything it reports.
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.
What this study adds
Evidence grade: Low
This is a trial of 15 participants. In this trial of 231 elderly patients with Alzheimer's disease, treatment with menatetrenone, risedronate, and calcium reduced the relative risk of nonvertebral fractures, including hip fractures. Reported effect size: increased by 5.7%; increased by 2.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sato, Y., Honda, Y., Umeno, K., Hayashida, N., Iwamoto, J., Takeda, T., et al. (2011). The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. The Kurume medical journal. https://doi.org/10.2739/kurumemedj.57.117
Vancouver
Sato Y, Honda Y, Umeno K, Hayashida N, Iwamoto J, Takeda T, et al. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. The Kurume medical journal. 2011. doi:10.2739/kurumemedj.57.117. PMID: 21778673.
BibTeX
@article{sato2011-21778673,
author = {Sato, Y. and Honda, Y. and Umeno, K. and Hayashida, N. and Iwamoto, J. and Takeda, T. and Matsumoto, H.},
title = {{The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial}},
journal = {The Kurume medical journal},
year = {2011},
doi = {10.2739/kurumemedj.57.117},
pmid = {21778673},
url = {https://doi.org/10.2739/kurumemedj.57.117}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81).
- Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture.
Why it matters
In this trial of 231 elderly patients with Alzheimer's disease, treatment with menatetrenone, risedronate, and calcium reduced the relative risk of nonvertebral fractures, including hip fractures. This treatment addresses fracture prevention in people with Alzheimer's disease, not the disease itself.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants15
- Effect sizeincreased by 5.7%; increased by 2.1%
- Evidence strengthLow
How this study scored 16/100
Retracted — do not rely on it. It scored 31 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. We have no data on impact for its field and year, so that was left out: it earned 29 of the 94 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (The Kurume medical journal) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 0 / 10 | Retracted — do not rely on it. PubMed indexes it as a Retracted Publication. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 15 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.4 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Hideo Matsumoto: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Keio University: institution h-index 735 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21778673) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 29 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 94 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2739/kurumemedj.57.117
- PubMed: 21778673
- Original source →
- Free full text: jstage.jst.go.jp →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.